Cognition Therapeutics Inc
CGTX
Company Profile
Business description
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
Contact
2500 Westchester Avenue
PurchaseNY10577
USAT: +1 412 481-2210
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
25
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,765.20 | 74.30 | 0.85% |
| CAC 40 | 7,763.84 | 26.64 | 0.34% |
| DAX 40 | 24,091.62 | 160.95 | 0.67% |
| Dow JONES (US) | 42,519.64 | 214.16 | 0.51% |
| FTSE 100 | 8,787.02 | 12.76 | 0.15% |
| HKSE | 23,682.34 | 169.85 | 0.72% |
| NASDAQ | 19,398.96 | 156.34 | 0.81% |
| Nikkei 225 | 37,813.92 | 367.11 | 0.98% |
| NZX 50 Index | 12,447.37 | 120.14 | 0.97% |
| S&P 500 | 5,970.37 | 34.43 | 0.58% |
| S&P/ASX 200 | 8,539.10 | 72.40 | 0.86% |
| SSE Composite Index | 3,376.53 | 14.56 | 0.43% |